Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
FoB were activated with 5 g/mL anti-IgM (Jackson Immunoresearch 715-006-020), 50 ng/mL CD40 ligand (Bio-techne 8230-CL-050) and 10 ng/mL IL-4 (Miltenyi Biotec 130-097-757)
This eye disease occurs when diabetes damages blood vessels in the retina
Full testing results and procedural documentation are furnished through the accompanying Certificate of Analysis (COA) with every shipment
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Lets break down what the science says, what experts recommend, and how to make informed decisions
US$ 24.50
US$ 21.06
US$ 26.60
US$ 24.25
US$ 21.23
US$ 26.29
